Predicted protein targets (top 11)
| gene | UniProt | supporting neighbours | confidence | |
|---|---|---|---|---|
| ▸ | GAA | P10253 | 1/20 | 0.39 |
| ▸ | L3MBTL1 | Q9Y468 | 1/20 | 0.39 |
| ▸ | ALDH1A1 | P00352 | 2/20 | 0.31 |
| ▸ | SMN1; SMN2 | Q16637 | 1/20 | 0.31 |
| ▸ | ATM | Q13315 | 1/20 | 0.31 |
| ▸ | DPP4 | P27487 | 1/20 | 0.31 |
| ▸ | ADH1B | P00325 | 1/20 | 0.31 |
| ▸ | ADH1C | P00326 | 1/20 | 0.31 |
| ▸ | ADH1A | P07327 | 1/20 | 0.31 |
| ▸ | ADH7 | P40394 | 1/20 | 0.31 |
| ▸ | HSD17B10 | Q99714 | 1/20 | 0.30 |
Click a target to see other patent compounds predicted against it — the reverse direction, in place.
Similar compounds — the chemically nearest patent molecules
Nearest neighbours by Morgan-fingerprint cosine across the patent-compound collection, with each neighbour's top predicted target and the predicted targets it shares with this molecule.
| Compound | similarity | top predicted | shared targets | |
|---|---|---|---|---|
| SCHEMBL18613034 | 0.92 | GAA (0.42) | GAAL3MBTL1ALDH1A1SMN1; SMN2ATM | |
| SCHEMBL11051416 | 0.92 | GAA (0.42) | GAAL3MBTL1ALDH1A1SMN1; SMN2ATM | |
| SCHEMBL24225594 | 0.92 | GAA (0.42) | GAAL3MBTL1ALDH1A1SMN1; SMN2ATM | |
| SCHEMBL13242284 | 0.88 | — | — | |
| SCHEMBL21799493 | 0.80 | KDM1A (0.36) | — | |
| SCHEMBL18684792 | 0.79 | GAA (0.43) | GAAL3MBTL1ALDH1A1SMN1; SMN2ATM | |
| SCHEMBL104716 | 0.79 | — | — | |
| SCHEMBL25086282 | 0.77 | MAPK1 (0.33) | — | |
| SCHEMBL21800038 | 0.77 | SMYD3 (0.37) | — | |
| SCHEMBL24368315 | 0.77 | ROCK2 (0.32) | — |
Similarity is cosine over the 2,048-bit Morgan fingerprint (≈ Tanimoto). Identical fingerprints score 1.00.
Patent provenance — the patents this molecule appears in, and who filed them
Claimed or disclosed in 3 patents. claimed = in the patent's claims; disclosed = body only.
| Patent | Title | Assignee | Published | Priority | Filing | Country | Status |
|---|---|---|---|---|---|---|---|
| EP-3995517-A1 | AMIDE COMPOUND, POLYMERIZABLE COMPOSITION, CURED PRODUCT, AND PRODUCTION METHOD THEREOF | ADEKA CORPORATION (JP) | 2022-05-11 | — | — | EP | disclosed |
| US-10005767-B2 | Compositions and methods for inhibition of the JAK pathway | RIGEL PHARMACEUTICALS, INC. (US) | 2018-06-26 | — | — | US | disclosed |
| US-20170137411-A1 | COMPOSITIONS AND METHODS FOR INHIBITION OF THE JAK PATHWAY | RIGEL PHARMACEUTICALS, INC. (US) | 2017-05-18 | — | — | US | disclosed |
Patent text — is the patent's own abstract consistent with the prediction?
For each of this compound's patents that has machine-readable text (2 of them — usually the abstract, not the full specification), we ask MedCPT which protein the text reads most about, and where the chemistry-predicted target lands among 4885 human targets. A high rank means the patent's own wording is consistent with the prediction — a weak, independent signal, not proof of activity.
| Patent | Title | Text reads most about | Predicted target · text-rank |
|---|---|---|---|
| US-20170137411-A1 | COMPOSITIONS AND METHODS FOR INHIBITION OF THE JAK PATHWAY | JAK3, JAK2, JAK1 | GAA 2139/4885L3MBTL1 3539/4885ALDH1A1 3988/4885 |
| US-10005767-B2 | Compositions and methods for inhibition of the JAK pathway | JAK3, JAK2, JAK1 | GAA 2139/4885L3MBTL1 3539/4885ALDH1A1 3988/4885 |
“Text reads most about” is the patent abstract's nearest protein in MedCPT space (background-debiased). Only ~1.4% of patents have machine-readable text, so most compounds won't have this panel.